Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

Equillium is implementing an amendment to the Type B portion of the EQUALISE study in LN patients to include newly diagnosed patients in addition to refractory patients.